share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George

EyePoint Pharmaceuticals | 4:持股变动声明-高管 Elston George
美股SEC公告 ·  05/28 22:38

Moomoo AI 已提取核心信息

George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
George Elston, the Chief Financial Officer of EyePoint Pharmaceuticals, completed a transaction involving the company's common stock on May 25, 2024. Elston exercised options to acquire 7,500 shares at no cost and subsequently sold 3,627 shares at a price of $11.16 per share. The sale resulted in a total market value of $40,477.32. Following these transactions, Elston's direct holdings in EyePoint Pharmaceuticals common stock amounted to 47,480 shares.
EyePoint Pharmicals首席财务官乔治·埃尔斯顿于2024年5月25日完成了一项涉及该公司普通股的交易。埃尔斯顿行使期权免费收购了7,500股股票,随后以每股11.16美元的价格出售了3,627股股票。此次出售的总市值为40,477.32美元。这些交易之后,埃尔斯顿直接持有的EyePoint Pharmicals普通股为47,480股。
EyePoint Pharmicals首席财务官乔治·埃尔斯顿于2024年5月25日完成了一项涉及该公司普通股的交易。埃尔斯顿行使期权免费收购了7,500股股票,随后以每股11.16美元的价格出售了3,627股股票。此次出售的总市值为40,477.32美元。这些交易之后,埃尔斯顿直接持有的EyePoint Pharmicals普通股为47,480股。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息